PAVmed Inc Dossier
Qualitative Analysis
Business overview
PAVmed Inc. (NASDAQ: PAVM) is a diversified commercial-stage medical technology company operating across the medical device, diagnostics, and digital health sectors. The company utilizes a shared services model to support its subsidiaries and advance a broad pipeline of medical technologies from concept to commercialization. Its primary business lines are driven by its key subsidiaries: Lucid Diagnostics Inc. (NASDAQ: LUCD), which focuses on cancer prevention diagnostics including the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device; and Veris Health Inc., a digital health company focused on personalized cancer care through remote patient monitoring using implantable biologic sensors. Additionally, PAVmed is advancing its own medical device portfolio, which includes the PortIO implantable intraosseous vascular access device and endoscopic esophageal imaging technology licensed from Duke University under its subsidiary Octeris.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Relaunching and advancing the company's medical device portfolio under dedicated leadership, specifically focusing on the PortIO implantable intraosseous vascular access device and newly licensed endoscopic esophageal imaging technology.
Expected impact: Diversifies PAVmed's commercial pipeline beyond diagnostics and digital health, establishing new high-growth medical device subsidiaries.
A multi-year restructuring process completed in early 2026 to eliminate all legacy convertible preferred stock and debt instruments, removing capital overhang.
Expected impact: Improves balance sheet health, simplifies the capital structure, and positions the company to better fund its subsidiaries and evaluate new asset acquisitions.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Exclusive worldwide license to multi-modality endoscopic imaging technology combining angle-resolved low coherence interferometry (a/LCI) with optical coherence tomography (OCT) to identify advanced esophageal precancer.
Terms: Executed through newly formed subsidiary Octeris, Inc., which will support ongoing sponsored research with Duke University.
Commercial phase deployment of the Veris Cancer Care Platform to enhance personalized cancer care through remote patient monitoring and launch a clinical registry.
Terms: Commercial terms not fully disclosed; includes expansion into additional clinical departments.